# Anti obesity Drugs Market

> Anti-obesity Drugs Market Research Report: Size, Share, Trend Analysis By Treatment Type (Appetite Suppressants (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others), by Drug Type (Prescription Drugs and Over the Counter Drugs), by Mechanism of Action (Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs), by Route of Administration (Oral and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 25.82%
- **2024:** $ 27.16 Billion
- **2025:** $ 34.17 Billion
- **2035:** $ 339.76 Billion
- **Key Players:** Companies such as Novo Nordisk (DK), Eli Lilly and Company (US), Pfizer Inc. (US), Boehringer Ingelheim (DE), Amgen Inc. (US), Sanofi (FR), Zafgen Inc. (US), Orexigen Therapeutics (US), GSK (GB) are some of the major participants in the global market.

**Report ID:** MRFR/HC/57644-CR · **Pages:** 184 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/anti-obesity-drugs-market-59415

---

## Market Summary

## **Anti-obesity Drugs Market Overview**

**The Anti-obesity Drugs Market was valued at USD 12.27 billion in 2024. The Anti-obesity Drugs Market industry is projected to grow from USD 13.33 billion in 2025 to USD 30.81 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.0% during the forecast period (2025-2035).**

The rising prevalence of obesity and increasing government initiatives and support are driving the growth of the Anti-obesity Drugs Market.

As per the Analyst at MRFR, the growing levels of obesity drive the market of anti-obesity drugs across the world mainly through the higher instances of individuals afflicted with obesity along with their increased health-related risk factors.

Estimated as of 2022, approximately 16% of all adults 18 years and older globally are said to be obese, constituting a very remarkable increase over preceding decades.

This increasing obesity rate is caused by a number of factors such as sedentary lifestyles, inappropriate diet, and environmental causes that lead to weight gain. The **World Health Organization (WHO)** reports that as of 2016, approximately 800 million people globally were affected by obesity, including more than 670 million adults and at least 120 million children and adolescents. This figure has continued to rise over the years.

 **FIGURE 1: ANTI-OBESITY DRUGS MARKET VALUE (2019-2035) USD BILLION**

** Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review**

## **Anti-obesity Drugs Market Opportunity**

### **FOCUS ON NON-SURGICAL OBESITY TREATMENTS**

Non-surgical obesity therapy has become increasingly popular as a substitute for invasive treatments, providing patients with effective weight control measures with fewer risks and increased accessibility.

The treatment mainly consists of pharmacological therapies, lifestyle changes, and medical devices, addressing patients who are inclined towards non-invasive therapies.

Among pharmacological therapies, **GLP-1 receptor agonists** have been a revolutionary development, drastically changing the dynamics of obesity treatment. Eli Lilly and Novo Nordisk, the two top drugmakers, have led the charge in creating cutting-edge anti-obesity medications that are revolutionizing treatment approaches.

Novo Nordisk's Wegovy (semaglutide), initially intended for **type 2 diabetes**, has shown considerable weight loss benefits and has become popular because it has been able to achieve weight loss of 15% or more in clinical trials.

Likewise, Eli Lilly's Mounjaro (tirzepatide) has demonstrated even higher weight loss efficacy by acting on both GLP-1 and GIP receptors, making it one of the most promising agents in the industry.

These drugs regulate hunger and enhance metabolic health, offering a long-term solution to weight loss without the need for surgery. In addition, non-surgical methods involve behavioral therapy, medically supervised dieting, and endoscopic treatments like intragastric balloons, which decrease stomach capacity temporarily to facilitate weight loss.

As obesity rates increase and concerns regarding the risks of bariatric surgery grow, non-surgical treatments are becoming increasingly accepted, backed by research, regulatory approvals, and the pharmaceutical industry's ongoing investment in obesity therapeutics.

The efficacy of drugs created by Eli Lilly and Novo Nordisk has again supported the viability and effectiveness of non-surgical obesity therapy, fueled industry growth and enhanced treatment possibilities for millions of patients globally.

## **Anti-obesity Drugs Market Segment Insights**

### **Anti-Obesity Drugs by Treatment Type Insights**

Based on Treatment Type, this segment includes Appetite Suppressants (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others.

The GLP-1 Receptor Agonists segment dominated the global market in 2024, while the Combination Drugs segment is projected to be the fastest–growing segment during the forecast period.

GLP-1 Receptor Agonists have become a cornerstone in the development of anti-obesity drugs, offering a highly effective solution for **weight management**. Initially designed to treat type 2 diabetes, these medications, including semaglutide (Wegovy) and liraglutide (Saxenda), work by mimicking the natural hormone GLP-1 to regulate appetite, food intake, and glucose metabolism.

Through mechanisms such as appetite suppression, increased satiety, and improved insulin sensitivity, GLP-1 receptor agonists have demonstrated significant efficacy in promoting sustained weight loss, with clinical trials showing reductions of up to 15-20% of body weight in patients.

Their dual benefit of managing obesity and enhancing metabolic health makes them particularly attractive for individuals with obesity-related conditions like type 2 diabetes and cardiovascular risk factors.

However, despite their promising outcomes, these medications require careful medical oversight due to potential side effects, making it crucial for healthcare providers to assess patient suitability for optimal results.

**FIGURE 2: ANTI-OBESITY DRUGS MARKET SHARE BY  2024 AND 2035 (USD BILLION)**

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

### **Anti-Obesity Drugs by Drug Type Insights**

Based on Drug Type, this segment includes Prescription Drugs and Over the Counter Drugs. The Prescription Drugs segment dominated the global market in 2024, while the Over the Counter Drugs segment is projected to be the fastest–growing segment during the forecast period.

Prescription anti-obesity drugs are a key component in the treatment of obesity, particularly for individuals who have been unable to achieve significant weight loss through lifestyle changes alone.

These medications are typically prescribed for patients with a body mass index (BMI) of 30 or higher, or 27 or higher with obesity-related health issues, such as diabetes or hypertension.

Among the most prescribed options are appetite suppressants like Phentermine, fat absorption inhibitors such as Orlistat, and GLP-1 receptor agonists like Semaglutide and Liraglutide. These drugs work by reducing hunger, enhancing feelings of fullness, or blocking fat absorption, helping patients achieve and maintain weight loss.

### **Anti-Obesity Drugs by Mechanism of Action Insights**

Based on Mechanism of Action, this segment includes Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs.

The Centrally Acting Anti-Obesity Drugs segment dominated the global market in 2024, while the Peripherally Acting Anti-Obesity Drugs segment is projected to be the fastest–growing segment during the forecast period.

Centrally acting anti-obesity medications are an important option in the treatment of obesity, targeting the brain's appetite-control centers to help manage hunger and food intake.

By affecting key neurotransmitters like norepinephrine, serotonin, and dopamine, these drugs work to reduce appetite, minimize cravings, and support weight loss.

Prominent examples include Phentermine, a short-term appetite suppressant, and Phentermine-Topiramate (Qsymia), a combination treatment that boosts appetite control and energy expenditure.

Bupropion-Naltrexone (Contrave), a combination of an antidepressant and opioid antagonist, works on the brain's reward system to help curb emotional eating and cravings.

While these drugs are effective, they require careful prescribing due to possible side effects, such as cardiovascular and mood-related issues. They are most effective when combined with lifestyle changes and behavioral interventions for sustained weight management.

### **Anti-Obesity Drugs by Route of Administration Insights**

Based on Route of Administration, this segment includes Oral and Subcutaneous. The Subcutaneous segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period.

The subcutaneous route of administration is emerging as a key player in the anti-obesity drugs market, driven by its ability to offer sustained and controlled drug release.

Subcutaneous injections, such as those used with GLP-1 receptor agonists like Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda), provide more consistent blood levels and enhanced efficacy in weight loss and metabolic control.

These injectable drugs reduce appetite, increase satiety, and regulate glucose, offering a significant advantage over oral medications, particularly for patients with more severe obesity or comorbidities like type 2 diabetes.

The subcutaneous route ensures better bioavailability and allows for less frequent dosing, improving patient adherence. While the method may present challenges in patient comfort and acceptance, the growing adoption of subcutaneous therapies reflects their strong position in the market, catering to patients seeking a more targeted and effective solution for weight management.

### **Anti-Obesity Drugs by Distribution Channel Insights**

Based on Distribution Channel, this segment includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

The Hospital Pharmacies segment dominated the global market in 2024, while the Online Pharmacies segment is projected to be the fastest–growing segment during the forecast period.

Hospital pharmacies play a crucial role as a distribution channel in the anti-obesity drug market, particularly for patients who require more specialized care or treatment regimens.

These pharmacies are integral in the distribution of prescription-based anti-obesity medications, including GLP-1 receptor agonists, centrally acting drugs, and combination therapies, often prescribed for individuals with severe obesity or obesity-related comorbidities, such as type 2 diabetes, hypertension, or cardiovascular disease.

Hospital pharmacies offer a highly controlled environment where patients can receive personalized counselling, precise dosing instructions, and tailored medication plans.

They also facilitate the monitoring of treatment progress, providing a high level of clinical support that ensures patient safety and adherence to prescribed **weight management protocols**.

### **Anti-obesity Drugs System Regional Insights**

Based on the Region, the global Anti-obesity Drugs are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa.

The North America dominated the global market in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are the rising prevalence of obesity and increasing government initiatives and support.

Government support and favorable policies also play a pivotal role in the market's expansion. Initiatives like Medicare’s proposal to cover anti-obesity drugs have opened doors for wider access to treatments, making these drugs more affordable and accessible to millions of Americans.

Additionally, the Food and Drug Administration's (FDA) approval of new anti-obesity medications, including GLP-1 receptor agonists like semaglutide (Wegovy), has driven significant growth, with these treatments demonstrating considerable effectiveness in weight reduction.

**FIGURE 3: ANTI-OBESITY DRUGS MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)**

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Spain, Italy, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.

## **Anti-obesity Drugs Key Market Players & Competitive Insights**

Many global, regional, and local vendors characterize the Anti-obesity Drugs Market. The market is highly competitive, with all the players competing to gain market share.

Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.

The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major competitors in the market are Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, CHEPLAPHARM Arzneimittel GmbH, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC are among others.

The Anti-obesity Drugs Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

### **Key Companies in the Anti-obesity Drugs Market include**

- Eli Lilly and Company
- AstraZeneca
- GSK Plc
- Gelesis
- CHEPLAPHARM Arzneimittel Arzneimittel GmbH
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc.
- KVK Tech, Inc.
- Currax Pharmaceuticals LLC
- VIVUS LLC

### **Anti-obesity Drugs Market Industry Developments**

January 2024: Rhythm Pharmaceuticals announced its plans to acquire LG Chem's rare genetic obesity drug, LB-54640, for up to $305 million.

This acquisition is set to strengthen Rhythm's MC4R pipeline, which already includes Imcivree (setmelanotide), a U.S. FDA-approved treatment for **genetic obesity disorders**.

March 2024: Cook Medical and Bentley have announced a distribution agreement for the BeBack Catheter in the United States. In the coming months, Cook Medical will take over the commercial responsibilities for this Bentley product.

July 2024: Currax Pharmaceuticals LLC announced the approval of an additional manufacturing site for CONTRAVE/MYSIMBA in the European Union (EU) and European Economic Area (EEA).

This new site doubles the current production capacity of CONTRAVE/MYSIMBA, ensuring continuity of supply and the ability to scale production as needed. An application for approval of this additional site by the U.S. Food & Drug Administration (FDA) is planned for Q3 2024.

November 2023: The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptor.

## **Anti-obesity Drugs Market Segmentation**

### **Anti-obesity Drugs by Treatment Type Outlook**

- Appetite Suppressants - Serotonin-Norepinephrine Reuptake Inhibitors - Selective Serotonin 2C Receptor Agonists - Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
- Lipase Inhibitors
- GLP-1 Receptor Agonists
- Combination Drugs

### **Anti-obesity Drugs by Drug Type Outlook**

- Prescription Drugs
- Over the Counter Drugs

### **Anti-obesity Drugs by Mechanism of Action Outlook**

- Centrally Acting Anti-Obesity Drugs
- Peripherally Acting Anti-Obesity Drugs

### **Anti-obesity Drugs by Route of Administration Outlook**

- Oral
- Subcutaneous

### **Anti-obesity Drugs by Distribution Channel Outlook**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

### **Anti-obesity Drugs Regional Outlook**

- North America - US - Canada
- Europe - Germany - France - UK - Spain - Italy - Russia - Rest of Europe
- Asia-Pacific - China - India - Japan - South Korea - Malaysia - Thailand - Indonesia - Rest of Asia-Pacific
- South America - Brazil - Mexico - Argentina - Rest of South America
- Middle East & Africa - GCC Countries - South Africa - Rest of MEA

## Market Drivers

### Rising Obesity Rates

The increasing prevalence of obesity is a primary driver for the Anti-obesity Drugs Industry . According to recent data, approximately 39% of adults are classified as overweight, with 13% being obese. This alarming trend is prompting healthcare systems to seek effective pharmacological interventions. The rising obesity rates are not only a health concern but also a significant economic burden, leading to increased healthcare costs and loss of productivity. 
 
As a result, there is a growing demand for anti-obesity medications that can assist in weight management and reduce obesity-related comorbidities. The global market is thus positioned to expand as more individuals seek medical solutions to combat obesity.

### Advancements in Drug Development

Innovations in drug development are significantly influencing the Anti-obesity Drugs Industry. Recent advancements have led to the emergence of novel pharmacological agents that target specific pathways involved in appetite regulation and energy expenditure. For instance, medications that utilize mechanisms such as GLP-1 receptor agonism have shown promising results in clinical trials, leading to increased efficacy and safety profiles. 
 
The introduction of these new drugs is expected to enhance treatment options for patients struggling with obesity, thereby expanding the market. As research continues to evolve, the global market may witness a surge in new product launches, catering to diverse patient needs and preferences.

### Regulatory Support and Approvals

Regulatory support plays a crucial role in shaping the market. Recent years have seen an increase in the approval of anti-obesity medications by regulatory bodies, which has encouraged pharmaceutical companies to invest in research and development. The streamlined approval processes for new drugs, coupled with incentives for developing obesity treatments, have fostered a more favorable environment for innovation.
 
As more drugs receive regulatory approval, the global market is likely to expand, providing patients with a wider array of treatment options. This regulatory landscape is essential for the growth of the market, as it directly impacts the availability and accessibility of effective medications.

### Increased Awareness of Health Risks

There is a growing awareness of the health risks associated with obesity, which is driving the Anti-obesity Drugs Market. Public health campaigns and educational initiatives have highlighted the link between obesity and various chronic diseases, such as diabetes, cardiovascular diseases, and certain cancers. This heightened awareness is leading individuals to seek medical advice and treatment options, including anti-obesity drugs.
 
Furthermore, healthcare providers are increasingly recommending pharmacotherapy as part of a comprehensive weight management plan. The global market is likely to benefit from this trend, as more patients become informed about the potential health benefits of weight loss and the role of medications in achieving their goals.

### Integration of Lifestyle Interventions

The integration of lifestyle interventions with pharmacotherapy is emerging as a key driver for the Anti-obesity Drugs Market. Healthcare professionals are increasingly recognizing that combining anti-obesity drugs with lifestyle modifications, such as diet and exercise, can lead to more sustainable weight loss outcomes.
 
This holistic approach not only enhances the effectiveness of medications but also improves patient adherence to treatment plans. As healthcare systems adopt this integrated model, the demand for anti-obesity drugs is expected to rise. The global market stands to benefit from this trend, as patients seek comprehensive solutions that address both pharmacological and behavioral aspects of weight management.

## Future Outlook

The  Global Anti-obesity Drugs Market size is projected to reach USD 3660.58 Billion by 2035, growing at a CAGR of 25.82%, driven by rising obesity rates, increased healthcare spending, and innovative drug development.

**New opportunities:**

- Expansion of telehealth services for obesity management Development of personalized anti-obesity medications Partnerships with fitness and wellness platforms for integrated solutions

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Treatment Type: GLP-1 Receptor Agonists (Largest) vs. Appetite Suppressants (Fastest-Growing)

In the Anti-obesity Drugs Market, GLP-1 Receptor Agonists have emerged as the largest segment, commanding 48% of market share due to their effective mechanisms in promoting weight loss and managing obesity-related comorbidities. Appetite Suppressants, while traditionally a well-established category, have seen a notable surge in demand, positioning them as the fastest-growing segment in recent years. This growth reflects a shift in consumer preferences towards non-invasive treatment options that can support weight management effectively. The rise in obesity rates globally has led to increased research and development in the anti-obesity drug sector, particularly for GLP-1 Receptor Agonists, which are gaining traction for their dual benefits in glycemic control and appetite regulation. Appetite Suppressants are similarly benefitting from heightened awareness about obesity and its health implications, which has led to a stronger focus on appetite regulation techniques. This dynamic landscape illustrates a robust competition among treatment types, with a clear trend leaning towards innovative solutions that cater to diverse patient needs.

GLP-1 Receptor Agonists (Dominant) vs. Appetite Suppressants (Emerging)

GLP-1 Receptor Agonists are currently positioned as the dominant force in the Anti-obesity Drugs Market, widely regarded for their efficacy in weight loss and metabolic improvement. They work by mimicking the glucagon-like peptide-1, which enhances insulin secretion and reduces appetite. This segment's strength lies in its clinical backing and positive patient outcomes. Alternatively, Appetite Suppressants are emerging as a focal point of growth, appealing to individuals seeking quick and convenient weight-loss options without the need for injections or invasive procedures. They operate by curbing hunger, making them particularly attractive in a market increasingly focused on non-invasive solutions. As both segments continue to evolve, they represent diverse approaches to tackling obesity, each with unique benefits to cater to various consumer preferences.

### By Drug Type: Prescription Drugs (Largest) vs. Over the Counter Drugs (Fastest-Growing)

In the Anti-obesity Drugs Market, Prescription Drugs hold a 71% portion of the market share due to their clinical efficacy and the effectiveness demonstrated in controlled environments. These medications are frequently prescribed by healthcare professionals, which reinforces their established position. On the other hand, [Over the Counter Drugs](../../../reports/otc-drugs-market-43711), although currently a smaller segment, are gaining traction with consumers seeking easier access to weight management solutions without needing a prescription. This shift can be attributed to increasing consumer awareness and the convenience of self-medication.

Prescription Drugs (Dominant) vs. Over the Counter Drugs (Emerging)

Prescription Drugs are considered the dominant force in the Anti-obesity Drugs Market, characterized by their proven ability to produce significant weight loss results in patients. These drugs typically require medical oversight, ensuring they are used responsibly and effectively. In contrast, Over the Counter Drugs represent an emerging trend, appealing to health-conscious consumers who prefer more accessible and less regulated options. This segment has expanded rapidly due to increased consumer awareness of obesity's health risks and a growing trend towards self-managed weight loss solutions. The rise of online retail and marketing strategies has further contributed to the visibility and acceptance of Over the Counter Drugs as viable alternatives.

### By Mechanism of Action: Centrally Acting Anti-Obesity Drugs (Largest) vs. Peripherally Acting Anti-Obesity Drugs (Fastest-Growing)

The Anti-obesity Drugs Market is primarily divided into two mechanisms of action: Centrally Acting and Peripherally Acting Anti-Obesity Drugs. Centrally Acting Anti-Obesity Drugs hold the largest market share of 63% due to their established efficacy in appetite suppression through central nervous system mechanisms. In contrast, Peripherally Acting Anti-Obesity Drugs are gaining traction rapidly, appealing to a segment of patients looking for alternatives that minimize central side effects, thus becoming a notable competitor in the global industry.

Centrally Acting (Dominant) vs. Peripherally Acting (Emerging)

Centrally Acting Anti-Obesity Drugs, such as those targeting neurotransmitter pathways in the brain, remain the dominant force in the anti-obesity market. Their long history of usage and substantial data supporting their effectiveness contribute to their leading position. On the other hand, Peripherally Acting Anti-Obesity Drugs are characterized by their mechanism of action that influences fat absorption. These emerging drugs are favored for their more favorable safety profile, attracting a growing demographic concerned about the side effects associated with central action drugs. This shift in preference highlights a noteworthy trend towards tolerable and patient-centric treatment options.

### By Route of Administration: Oral (Largest) vs. Subcutaneous (Fastest-Growing)

In the Anti-obesity Drugs Market, the distribution of market share among routes of administration shows a distinct preference for oral formulations. Oral anti-obesity drugs represent the largest segment with 67% market share due to their ease of use, patient compliance, and established history in obesity treatment. Subcutaneous drugs, while trailing in current market share, are gaining traction because of advancements in delivery systems and the potential for improved efficacy in treatment protocols. As the market evolves, both routes of administration showcase unique strengths that appeal to different patient needs.

Route of Administration: Oral (Dominant) vs. Subcutaneous (Emerging)

Oral administration remains the dominant route in the Anti-obesity Drugs Market, favored for its convenience and widespread acceptance among patients. This route allows for easy self-administration and a well-established therapeutic profile, making it a staple in obesity management. Conversely, subcutaneous administration is emerging rapidly as a viable alternative. It often facilitates quicker onset of action and can enhance bioavailability of certain drug formulations. The development of devices that simplify the subcutaneous delivery process, along with clinical validation of its efficacy, is driving this segment's growth, making it an appealing option for obesity treatment in the coming years.

### By Distribution Channel: Retail Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

The distribution of the anti-obesity drugs market across various channels shows a significant preference for retail pharmacies, which currently dominate wtih 58% market share . Their established presence and customer trust lead to higher sales volumes compared to hospital pharmacies, which tend to cater to a more specific patient demographic. Online pharmacies, while holding a smaller market share at present, are expanding rapidly as consumers become more comfortable with purchasing medications online, especially with the growing emphasis on convenience and accessibility.

Retail Pharmacies: Dominant vs. Online Pharmacies: Emerging

Retail pharmacies are characterized by their widespread availability and direct access to consumers, making them the preferred choice for many patients seeking anti-obesity medications. They benefit from foot traffic and personal interaction, which builds customer loyalty. On the other hand, online pharmacies are becoming an emerging force within the distribution landscape. They offer the convenience of discreet ordering and home delivery, appealing to a growing segment of health-conscious consumers. The increase in smartphone usage and e-commerce has enabled online pharmacies to gain traction, providing competitive pricing and greater access to a broader range of anti-obesity drugs.

## Regional Market Share Analysis

Based on the Region, the global Anti-obesity Drugs are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa.

North America leads in the Anti obesity Drugs Market size, accounting for over 44.92% of the global revenue in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are the rising prevalence of obesity and increasing government initiatives and support.

- According to the Centers for Disease Control and Prevention, more than 42% of adults in the United States are living with obesity, significantly increasing healthcare demand for weight management therapies. Strong healthcare infrastructure, growing reimbursement support, and expanding awareness regarding obesity-related complications continue accelerating anti-obesity drug adoption across North America.

Government support and favorable policies also play a pivotal role in the global industry expansion. Initiatives like Medicare’s proposal to cover anti-obesity drugs have opened doors for wider access to treatments, making these drugs more affordable and accessible to millions of Americans.

- The World Health Organization reports that nearly 60% of adults and one in three children in Europe are overweight or obese. Rising healthcare expenditures, increasing awareness regarding obesity-linked chronic diseases, and stronger preventive healthcare initiatives are supporting expanding adoption of anti-obesity therapeutics throughout the European region.

Additionally, the Food and Drug Administration's (FDA) approval of new anti-obesity medications, including GLP-1 receptor agonists like semaglutide (Wegovy), has driven significant growth, with these treatments demonstrating considerable effectiveness in weight reduction.

**FIGURE 3: ANTI-OBESITY DRUGS MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)**

Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Spain, Italy, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Anti-obesity Drugs Market. The global industry is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. 
 
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major competitors in the global industry are Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, CHEPLAPHARM Arzneimittel GmbH, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC are among others. The Anti-obesity Drugs Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

January 2024: Rhythm Pharmaceuticals announced its plans to acquire LG Chem's rare genetic obesity drug, LB-54640, for up to $305 million.

This acquisition is set to strengthen Rhythm's MC4R pipeline, which already includes Imcivree (setmelanotide), a U.S. FDA-approved treatment for **genetic obesity disorders**.

March 2024: Cook Medical and Bentley have announced a distribution agreement for the BeBack Catheter in the United States. In the coming months, Cook Medical will take over the commercial responsibilities for this Bentley product.

July 2024: Currax Pharmaceuticals LLC announced the approval of an additional manufacturing site for CONTRAVE/MYSIMBA in the European Union (EU) and European Economic Area (EEA).

This new site doubles the current production capacity of CONTRAVE/MYSIMBA, ensuring continuity of supply and the ability to scale production as needed. An application for approval of this additional site by the U.S. Food & Drug Administration (FDA) is planned for Q3 2024.

November 2023: The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptor.

## Report Scope

| MARKET SIZE 2024 | 27.16(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 34.17(USD Billion) |
| MARKET SIZE 2035 | 339.76(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 25.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novo Nordisk (DK), Eli Lilly and Company (US), Pfizer Inc. (US), Boehringer Ingelheim (DE), Amgen Inc. (US), Sanofi (FR), Zafgen Inc. (US), Orexigen Therapeutics (US), GSK (GB) |
| Segments Covered | Treatment Type, Drug Type, Mechanism of Action, Route of Administration, Distribution Channel |
| Key Market Opportunities | Emergence of novel pharmacotherapies addressing diverse obesity phenotypes in the market. |
| Key Market Dynamics | Rising consumer demand for effective anti-obesity solutions drives innovation and regulatory scrutiny in the pharmaceutical sector. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Anti-obesity Drugs Market in 2025?**
A: The market is valued at approximately 27.16 USD Billion in 2024.

**Q: What is the projected market size for the Anti-obesity Drugs Market by 2035?**
A: The market is projected to reach around 339.76 USD Billion by 2035.

**Q: What is the expected CAGR for the Anti-obesity Drugs Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 25.82%.

**Q: Which companies are the key players in the Anti-obesity Drugs Market?**
A: Key players include Novo Nordisk, Eli Lilly and Company, Pfizer Inc., and Boehringer Ingelheim.

**Q: What are the main segments of the Anti-obesity Drugs Market?**
A: The main segments include Treatment Type, Drug Type, Mechanism of Action, Route of Administration, and Distribution Channel.

**Q: How much revenue did Appetite Suppressants generate in 2024?**
A: Appetite Suppressants generated approximately 5.0 USD Billion in revenue in 2024.

**Q: What is the revenue projection for GLP-1 Receptor Agonists by 2035?**
A: GLP-1 Receptor Agonists are projected to generate around 100.0 USD Billion by 2035.

**Q: What is the market size for Prescription Drugs in the Anti-obesity Drugs Market?**
A: Prescription Drugs accounted for approximately 20.0 USD Billion in 2024.

**Q: What distribution channel is expected to perform best in the Anti-obesity Drugs Market?**
A: Online Pharmacies are projected to generate about 135.86 USD Billion by 2035.

**Q: What is the revenue for Centrally Acting Anti-Obesity Drugs in 2024?**
A: Centrally Acting Anti-Obesity Drugs generated approximately 10.86 USD Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/anti-obesity-drugs-market-59415*